Cardiac biomarkers: a contemporary status report

The field of cardiac biomarkers has grown by leaps and bounds in the past two decades. In this review we try to summarize the explosion of emerging knowledge and address the roles of some of the biomarkers that have either proven or potential utility. We detail some of the markers of ischemia, hemodynamic markers of heart failure, inflammatory markers, and the novel and innovative approach of combining these for a multimarker strategy. At the end of this review we highlight some of the biomarker-guided approaches and strategies that might lead to better and more-effective care of patients.

[1]  E. Topol,et al.  Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. , 1997, The American journal of cardiology.

[2]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, New England Journal of Medicine.

[3]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[4]  A. Maisel,et al.  B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure. , 2004, Congestive heart failure.

[5]  Shuiping Zhao,et al.  Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[6]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[7]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[8]  D. Morrow,et al.  Brain Natriuretic Peptide Measurement in Acute Coronary Syndromes: Ready for Clinical Application? , 2002, Circulation.

[9]  D. Barnett,et al.  Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. , 2000, European heart journal.

[10]  S. Ogawa,et al.  C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.

[11]  N. Kleiman,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[12]  M. Sabatine,et al.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[13]  R. Califf,et al.  Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. , 1999, The American journal of cardiology.

[14]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[15]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[16]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[17]  A. Rebuzzi,et al.  Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. , 1998, The American journal of cardiology.

[18]  M. Sabatine,et al.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.

[19]  Pablo Avanzas,et al.  Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. , 2004, International journal of cardiology.

[20]  A. Jaffe,et al.  Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. , 1994, The New England journal of medicine.

[21]  A. Maisel,et al.  B-Type Natriuretic Peptide: The Level and the Drug— Partners in the Diagnosis and Management of Congestive Heart Failure , 2004 .

[22]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[23]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[24]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[25]  M. Ohyanagi,et al.  Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.

[26]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[27]  A. Remppis,et al.  Diagnostic Efficiency of Troponin T Measurements in Acute Myocardial Infarction , 1991, Circulation.

[28]  TorbjørnOmland,et al.  N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .

[29]  E. Antman,et al.  Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. , 2000, Clinical chemistry.

[30]  Alan S Maisel,et al.  A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction. , 2004, American heart journal.

[31]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[32]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[33]  C. Heeschen,et al.  Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.

[34]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[35]  M. Bissell.  Ischemia Modified Albumin for the Assessment of Patients Presenting to the Emergency Department With Acute Chest Pain But Normal or Nondiagnostic 12-lead Electrocardiograms and Negative Cardiac Troponin T , 2006 .

[36]  R. Califf,et al.  Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. , 2003, Journal of the American College of Cardiology.

[37]  E. Antman,et al.  B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. , 2004, Journal of the American College of Cardiology.

[38]  E. Antman,et al.  Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. , 2000, Journal of the American College of Cardiology.

[39]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[40]  V. Hasselblad,et al.  Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. , 2003, Journal of the American College of Cardiology.

[41]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[42]  David A Morrow,et al.  Future of Biomarkers in Acute Coronary Syndromes Moving Toward a Multimarker Strategy , 2003, Circulation.

[43]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[44]  E. Braunwald,et al.  Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. , 2004, Journal of the American College of Cardiology.

[45]  A. Maisel,et al.  B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. , 2005, European heart journal.

[46]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[47]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[48]  F. Hetzel,et al.  Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. , 2001, American heart journal.

[49]  C. Boissonnet,et al.  Independent prognostic value of elevated C-reactive protein in unstable angina. , 1999, Circulation.

[50]  Wendy R. Sanhai,et al.  Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. , 2001, Clinical chemistry.

[51]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[52]  H. Thode,et al.  Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. , 1994, Annals of emergency medicine.

[53]  N. Arakawa,et al.  Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. , 1994, Cardiology.

[54]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[55]  L. Wallentin,et al.  Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). , 2002, The American journal of cardiology.

[56]  K. Huber,et al.  N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. , 2004, Journal of the American College of Cardiology.

[57]  M. Hamada,et al.  Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. , 1995, Clinical science.

[58]  M. Sabatine,et al.  Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. , 2003, Clinical chemistry.

[59]  L. Wallentin,et al.  Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.

[60]  W. Gibler,et al.  Chest pain centers: diagnosis of acute coronary syndromes. , 2000, Annals of emergency medicine.

[61]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[62]  A. Go,et al.  The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. , 2001, Journal of the American College of Cardiology.

[63]  J. Hollander,et al.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.

[64]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[65]  L. Køber,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease , 2005 .

[66]  P. Shekelle,et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.

[67]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[68]  S. Mudaliar,et al.  Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[69]  A. Jaffe,et al.  Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study , 2001 .

[70]  Joseph P Ornato,et al.  Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. , 2004, Journal of the American College of Cardiology.

[71]  A. Jaffe,et al.  Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. , 2001, Circulation.